Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon

HIV Medicine

Volumn 15, Issue 8, 2014, Pages 478-487

  Meresse, M ^a,b,c   March, L ^a,b,c   Kouanfack, C ^d   Bonono, R C ^e   Boyer, S ^a,b,c,k   Laborde Balen, G ^f   Aghokeng, A ^g,h,j   Suzan Monti, M ^a,b,c   Delaporte, E ^g,i   Spire, B ^a,b,c,k   Carrieri, M P ^a,b,c,k   Laurent, C ^g   Biwole Sida M ^d   Koulla Shiro, S ^d   Bourgeois, A ^g   Peeters, M ^g   Dontsop, M ^h   Kaze S ^h   Mben, J M ^h   Edoul, M G ^j   Mpoudi Ngole E ^j   Tongo, M ^j   Marcellin, F ^k   Moatti, J P ^k   Abe C ^e   Abega, S C ^e   Bonono, C R ^e   Mimcheu, H ^e   Yebga, S Ngo ^e   Bile, C Paul ^e   Abada, S ^l   Abanda, T ^l   Baga, J ^l   Fouda, P Bilobi ^l   Mve, P Etong ^l   Tama, G Fetse ^l   Kemo, H ^l   Ongodo, A ^l   Tadewa, V ^l   Voundi, H D ^l   Ambani, A ^l   Atangana, M ^l   Biaback, J C ^l   Kennedy, M ^l   Kibedou, H ^l   Kounga, F ^l   Abanda, M Maguip ^l   Mamang, E ^l   Mikone, A ^l   Tang, S ^l   Tchuangue, E ^l   Tchuenko, S ^l   Yakan, D ^l   Assandje, J ^l   Ebana, S ^l   Ebo'o, D ^l   Etoundi, D ^l   Ngama, G ^l   Ango, P Mbarga ^l   Mbezele, J ^l   Mbong, G ^l   Moung, C ^l   Ekotto, N ^l   Balla, G Nguemba ^l   Ottou, G ^l   Tigougmo, M ^l   Beyala, R ^l   Ebene, B ^l   Effemba, C ^l   Eyebe, F ^l   Hadjaratou, M M ^l   Mbarga, T ^l   Metou, M ^l   Ndam, M ^l   Ngoa, B ^l   Ngock, E B ^l   Obam, N ^l   Abomo, A M ^l   Angoula, G ^l   Ekassi, E ^l   Essama, ^l   Lentchou, J J ^l   Mvilongo, I ^l   Ngapou, J ^l   Ntokombo, F ^l   Ondoua, V ^l   Palawo, R ^l   Sebe, S ^l   Sinou, E ^l   Wankam, D ^l   Zobo, I ^l   Akono, B ^l   Ambani, A L ^l   Bilock, L ^l   Bilo'o, R ^l   Boombhi, J ^l   Fouda, F X ^l   Guitonga, M ^l   Mad'aa, R ^l   Metou'ou, D R ^l   Mgbih, S ^l   Noah, A ^l   Tadena, M ^l   Ntcham, ^l   Elime, G Ambassa ^l   Bonongnaba, A A ^l   Foaleng, E ^l   Heles, R M ^l   Messina, R ^l   Ndankou, O Nana ^l   Ngono, S A ^l   Menounga, D Ngono ^l   Sil, S S ^l   Tchouamou, L ^l   Zambou, B ^l   Abomo, R ^l   Ambomo, J ^l   Beyomo, C ^l   Eloundou, P ^l   Ewole, C ^l   Fokom, J ^l   Mvoto, M ^l   Ngadena, M ^l   Nyolo, R ^l   Onana, C ^l   Oyie, A ^l   Antyimi, P ^l   Mbatonga, S Bella ^l   Bikomo, M ^l   Bodo, Y Molo ^l   Ntang, S Ndi ^l   Ndoudoumou, P ^l   Ndzomo, L ^l   Ngolo, S O ^l   Nkengue, M ^l   Nkoa, ^l   Tchinda, Y ^l   more..

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

^e Burundi   (Cameroon)

^f French Ministry of Foreign Affairs   (Cameroon)

^g INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^h Institut de Recherche pour le Developpement Cameroon   (Cameroon)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j Institute of Medical Research and Medicinal Plant Studies Yaounde   (Cameroon)

^k INSERM   (France)

^l District Hospital   (Cameroon)

more..

Author keywords

Adherence; Africa; Antiretroviral; HIV; Resistance

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AFRICA; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; TIME; TREATMENT FAILURE; VIRUS LOAD; ANTIVIRAL RESISTANCE; CAMEROON; DRUG EFFECTS; GENETICS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERVIEW; PROCEDURES; PUBLIC HOSPITAL; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAMEROON; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HOSPITALS, DISTRICT; HUMANS; INTERVIEWS AS TOPIC; MALE; MEDICATION ADHERENCE; TIME FACTORS; VIRAL LOAD;

EID: 84906322096     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12140     Document Type: Article

References (41)

1. El-Khatib Z, Ekstrom AM, Ledwaba J etal. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 2010; 24: 1679-1687.
2. Bourgeois A, Laurent C, Mougnutou R etal. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Antivir Ther (Lond) 2005; 10: 335-341.
3. Laurent C, Kouanfack C, Koulla-Shiro S etal. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364: 29-34.
4. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146: 564-573.
5. Maleewong U, Kulsomboon V, Teerawattananon Y. The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand. J Med Assoc Thai 2008; 91 (Suppl 2): S126-S138.
6. Colebunders R, Kamya MR, Laurence J etal. First-line antiretroviral therapy in Africa-how evidence-base are our recommendations? AIDS Rev 2005; 7: 148-154.
7. Spacek LA, Shihab HM, Kamya MR etal. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006; 42: 252-259.
8. Nachega JB, Stein DM, Lehman DA etal. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses 2004; 20: 1053-1056.
9. Parruti G, Manzoli L, Toro PM etal. Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: predictors and impact on virologic response and relapse. AIDS Patient Care STDS 2006; 20: 48-56.
10. Stringer JSA, Zulu I, Levy J etal. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296: 782-793.
11. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006; 20: 1163-1169.
12. Patel AK, Pujari S, Patel K etal. Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort. J Assoc Physicians India 2006; 54: 915-918.
13. Delaugerre C. Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor. Med Mal Infect 2010; 40 (Suppl 1): S1-10.
14. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001; 358: 410-414.
15. Chien CV. HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare? PLoS ONE 2007; 2: e278.
16. Bangsberg DR, Charlebois ED, Grant RM etal. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003; 17: 1925-1932.
17. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003; 37: 1112-1118.
18. Harrigan PR, Hogg RS, Dong WW etal. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191: 339-347.
19. Parienti J-J, Massari V, Descamps D etal. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38: 1311-1316.
20. Oyugi JH, Byakika-Tusiime J, Ragland K etal. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21: 965-971.
21. Meresse M, Carrieri MP, Laurent C etal. Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon. Antivir Ther (Lond) 2013; 18: 29-37.
22. Bangsberg DR, Mills EJ. Long-term adherence to antiretroviral therapy in resource-limited settings: a bitter pill to swallow. Antivir Ther (Lond) 2013; 18: 25-28.
23. Carrieri MP, Raffi F, Lewden C etal. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther (Lond) 2003; 8: 585-594.
24. Laurent C, Kouanfack C, Laborde-Balen G etal. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis 2011; 11: 825-833.
25. WHO. Antiretroviral therapy for HIV infection in adults and adolescents, Recommendations for a public health approach (2006 revision). 2006. Available at: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf (accessed 20 February 2014).
26. French National Agency for Research on AIDS and Viral Hepatitis. HIV-1 genotypic drug resistance interpretation's algorithms. 2010. Available at: http://www.hivfrenchresistance.org/tab2010.html (accessed 20 February 2014).
27. Carrieri P, Cailleton V, Le Moing V etal. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr 2001; 28: 232-239.
28. Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 2011; 25: 279-290.
29. Clotet B. Strategies for overcoming resistance in HIV-1 infected patients receiving HAART. AIDS Rev 2004; 6: 123-130.
30. Wouters E, Van Damme W, van Rensburg D, Meulemans H. Impact of baseline health and community support on antiretroviral treatment outcomes in HIV patients in South Africa. AIDS 2008; 22: 2545-2548.
31. Wouters E, van Loon F, van Rensburg D, Meulemans H. Community support and disclosure of HIV serostatus to family members by public-sector antiretroviral treatment patients in the Free State Province of South Africa. AIDS Patient Care STDS 2009; 23: 357-364.
32. Hong SY, Jonas A, Dumeni E etal. Population-based monitoring of HIV drug resistance in namibia with early warning indicators. J Acquir Immune Defic Syndr 2010; 55: 27-31.
33. World Health Organization. World Health Organization global strategy for the surveillance and monitoring of HIV drug resistance. 2012. Available at: http://apps.who.int/iris/bitstream/10665/77349/1/9789241504768_eng.pdf (accessed 20 February 2014).
34. Reynolds SJ, Nakigozi G, Newell K etal. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23: 697-700.
35. Hawkins C, Murphy RL. Management of antiretroviral failure and resistance in developing countries. Curr Opin HIV. AIDS 2009; 4: 538-544.
36. Rewari BB, Bachani D, Rajasekaran S, Deshpande A, Chan PL, Srikantiah P. Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing. J Acquir Immune Defic Syndr 2010; 55: 610-614.
37. Boullé C, Kouanfack C, Laborde-Balen G etal. Prediction of HIV drug resistance based on virologic, immunologic, clinical, and/or adherence criteria in the stratall ANRS 12110/ESTHER trial in Cameroon. Clin Infect Dis 2013; 57: 604-607.
38. Calmy A, Ford N, Hirschel B etal. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007; 44: 128-134.
39. Johannessen A, Naman E, Kivuyo S etal. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis 2009; 9: 108.
40. Soria A, Porten K, Fampou-Toundji J-C etal. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Antivir Ther (Lond) 2009; 14: 339-347.
41. Gupta A, Saple DG, Nadkarni G etal. One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India. AIDS Res Hum Retroviruses 2010; 26: 25-31.